---
title: The Effect of Home-based Rehabilitation Program After COVID-19 Infection
nct_id: NCT05317975
overall_status: TERMINATED
phase: NA
sponsor: National Taiwan University Hospital
study_type: INTERVENTIONAL
primary_condition: COVID-19
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05317975.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05317975"
ct_last_update_post_date: 2025-02-19
last_seen_at: "2026-05-12T07:14:48.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Home-based Rehabilitation Program After COVID-19 Infection

**Official Title:** The Cardiopulmonary Function Outcome and the Effect of Two Modules of Home-based Rehabilitation Programs in Patients After COVID-19 Infection - A Randomized and Controlled Trial.

**NCT ID:** [NCT05317975](https://clinicaltrials.gov/study/NCT05317975)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Recruitment difficulties and insufficient funding.
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 13
- **Lead Sponsor:** National Taiwan University Hospital
- **Conditions:** COVID-19
- **Start Date:** 2021-07-15
- **Completion Date:** 2025-02-17
- **CT.gov Last Update:** 2025-02-19

## Brief Summary

To follow up the cardiopulmonary function after coronavirus disease 2019 (CoVID-19) infection and compare the effect of a 12-week home-based cardiopulmonary with or without add-on remote rehabilitation on the cardiopulmonary function, emotion and quality of outcome.

## Detailed Description

The investigators will recruit the patients post-CoVID infection for a cardiopulmonary function evaluation and a home-based rehabilitation program. The investigators hypothesize that an add-on remote rehabilitation on a home-based rehabilitation has a better effect than a home-based rehabilitation alone on the compliance rate for the exercise, and also a better outcome in terms of cardiopulmonary function testing, 6-minute walking test, physical activities and quality of life, as well as less dyspnea, depression and anxiety.

## Eligibility

- **Minimum age:** 20 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion criteria:

1. ≥ 20 years of age.
2. COVID-19 survivor after de-isolation at post-acute stage about to be discharged or already at outpatient follow-up who still have symptoms or exercise intolerance.

Exclusion criteria:

1. Unable to cooperate with rehabilitation or evaluation.
2. Dependent in basic activities of living before infection (Premorbid Barthel index \<80).
3. End stage patient, with life expectancy less than 1 year.
4. Having contraindications for exercise according to the evaluation of a physician.
```

## Arms

- **Add-on telerehabilitation combined with usual home-based rehabilitation** (EXPERIMENTAL) — Add-on telerehabilitation combined with usual home-based rehabilitation
- **Stand-alone usual home-based rehabilitation** (EXPERIMENTAL) — Stand-alone usual home-based rehabilitation
- **Usual care** (NO_INTERVENTION) — Usual care

## Interventions

- **Add-on telerehabilitation and home-based rehabilitation** (BEHAVIORAL) — 1. 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
2. Add-on telerehabilitation for instruction and supervision of exercise training
- **Home-based rehabilitation alone** (BEHAVIORAL) — 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.

## Primary Outcomes

- **Change of 6-minute walking test (6MWT) and exercise capacity** _(time frame: The change in 6MWT and peak oxygen uptake will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)_ — The distance of a 6-minute walking test and peak oxygen uptake according to cardiopulmonary exercise test will be assessed before intervention (12-week rehabilitation course), 12 weeks, 6 months and 12 months after intervention.

## Secondary Outcomes

- **Dyspnea scale** _(time frame: The change in mMRC will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)_
- **Fatigue** _(time frame: The change in BFI will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)_
- **Depression and anxiety** _(time frame: The change in PHQ-9 and GAD-7 will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)_
- **Cognitive evaluation** _(time frame: The change in MoCA will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)_
- **Quality of life evaluation** _(time frame: The change in EQ-5D will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)_
- **Grip strength** _(time frame: The change in grip strength will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)_

## Locations (1)

- National Taiwan University Hospital, Taipei, Taiwan

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.national taiwan university hospital|taipei||taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05317975.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05317975*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*